Real-World Incidence of CRS and Icans across Commercial CAR-T Products in B-cell Malignancies and Multiple Myeloma: A Single-Center Analysis

Key Points

• The incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in B-cell malignancies.
• Among various CAR-T products, CRS occurred in 45% and ICANS in 25% of treated cases, highlighting significant side effects.
• A retrospective analysis of patient records identified patterns of CRS and ICANS across CAR-T therapies for multiple myeloma.
• Understanding these incidences is crucial for improving patient outcomes and managing treatment plans effectively.